Brief: Hanall Biopharma Reports Third Quarter 2022 Results
15/11/2022 12:07
Nov 15 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA REPORTS THIRD QUARTER 2022 RESULTS AND
PROVIDES
BUSINESS UPDATE
* HANALL BIOPHARMA CO LTD Q3 REVENUE KRW 29.6 BILLION
Source text for Eikon: ID:nPn5KYGq4a
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies